Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubidium salt is a metal compound being investigated for its therapeutic potential in treating ulcerative colitis, a chronic inflammatory bowel disease. It works by modulating the intestinal flora, increasing the abundance of beneficial bacteria such as Lactobacillus and Bifidobacterium, while inhibiting harmful bacteria like Enterobacteriaceae and Escherichia coli. Additionally, it directly weakens pathogenic bacteria by reducing the expression of their virulence factors (e.g., fimH, invA, hilA) and virulence genes (e.g., acrA, ompR). These actions lead to an increase in short-chain fatty acids, improved intestinal barrier function, and a reduction in inflammatory markers, ultimately alleviating the symptoms of ulcerative colitis. The specific rubidium salt studied was purified from Minerals Containing Rubidium (MCR) from Guangxi Yuechengling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rubidium salt.